Imexpharm (STC:IMP) Cyclically Adjusted PB Ratio: (As of Jul. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STC:IMP Imexpharm Corp STC:IMP
98 GF Score
Price ₫35,800.00
GF Value ₫53,201.83
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Imexpharm Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Imexpharm  (STC:IMP) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Imexpharm Cyclically Adjusted PB Ratio Related Terms


Imexpharm Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Imexpharm's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imexpharm Cyclically Adjusted PB Ratio Chart

Imexpharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.32 2.37 2.21 3.81 4.01

Imexpharm Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.01 4.05 4.01 4.07 0.00

STC:IMP vs ZTS, UTHR: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Imexpharm's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imexpharm Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Imexpharm's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Imexpharm's Cyclically Adjusted PB Ratio falls into.


STC:IMP
98GF Score
Imexpharm Corp STC:IMP
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imexpharm Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Imexpharm's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Imexpharm's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=13533.875/333.9520*333.9520
=13,533.875

Current CPI (Jun. 2026) = 333.9520.

Imexpharm Quarterly Data

Book Value per Share CPI Adj_Book
201609 7,758.981 241.428 10,732.505
201612 8,386.423 241.432 11,600.213
201703 9,057.073 243.801 12,406.133
201706 9,067.109 244.955 12,361.369
201709 9,215.200 246.819 12,468.386
201712 9,262.759 246.524 12,547.731
201803 9,401.360 249.554 12,580.856
201806 9,585.237 251.989 12,702.971
201809 9,819.870 252.439 12,990.723
201812 9,989.063 251.233 13,277.983
201903 10,229.589 254.202 13,438.886
201906 9,762.527 256.143 12,728.107
201909 10,010.848 256.759 13,020.547
201912 10,351.740 256.974 13,452.662
202003 10,624.757 258.115 13,746.426
202006 10,535.558 257.797 13,647.834
202009 11,008.170 260.280 14,124.022
202012 11,236.121 260.474 14,405.757
202103 11,507.890 264.877 14,508.934
202106 11,015.416 271.696 13,539.471
202109 11,218.771 274.310 13,658.018
202112 11,651.181 278.802 13,955.908
202203 11,992.724 287.504 13,930.221
202206 11,493.465 296.311 12,953.504
202209 11,855.709 296.808 13,339.390
202212 12,300.725 296.797 13,840.611
202303 12,806.054 301.836 14,168.646
202306 12,612.896 305.109 13,805.236
202309 13,065.492 307.789 14,176.099
202312 13,535.348 306.746 14,735.829
202403 13,937.401 312.332 14,902.165
202406 13,490.448 314.175 14,339.658
202409 13,960.696 315.301 14,786.513
202412 14,175.270 315.605 14,999.318
202503 14,593.824 319.799 15,239.687
202506 13,779.330 322.561 14,265.937
202509 14,278.598 324.800 14,680.931
202512 14,976.541 324.054 15,433.989
202603 15,444.167 330.213 15,619.041
202606 13,533.875 333.952 13,533.875

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Imexpharm (STC:IMP) Overvalued in 2026?

Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued. The current stock price of ₫35,800.00 is trading 32.7% below its estimated GF Value™ of ₫53,201.83. GuruFocus considers Imexpharm to be Significantly Undervalued.

Key valuation signals for STC:IMP:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₫53,201.83 vs. price of ₫35,800.00 (32.7% below fair value)
  • GF Score™: 98/100 with 2 warning signs

No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Imexpharm Business Description

Address 4 Road 30/04 Street Ward 1, Cao Lanh City, Dongthap, VNM
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
98GF Score

Get the complete analysis for STC:IMP

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫35,800.00
Price
₫53,201.83
GF Value